State-Dependent Etomidate Binding in GABAA Receptors Probed with Cysteine Substitution and Protection from Modification  by Stewart, Deirdre et al.
Wednesday, February 6, 2012 637aand the muscle nicotinic acetylcholine receptor (AChR) with pore blockers.
From the comparative analysis of these results, it appears as though the muscle
AChR and GLIC have very similar open-channel pore structures, whereas the
open-channel pore of ELIC seems much narrower, and thus, closer to the struc-
tural model of ELIC in its closed state. Hence, it is likely that the closed-to-
open conformational change of ELIC at the level of the pore domain is subtler
than the one that could be predicted if ELIC were to adopt a GLIC-like structure
in the open state.
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The outermost lipid-exposed M4 alpha-helix in the transmembrane domain of
each subunit of the nicotinic acetylcholine receptor (nAChR) plays an impor-
tant role in channel gating and may provide the allosteric link between
nAChR function and lipid sensitivity. The C-terminal residues of M4 appear
to be particularly important, with deletion mutations abrogating channel
activity. Post-M4 may influence channel gating via direct interactions with
the Cys-loop of the agonist binding domain, a structure that plays a key
role allosterically translating agonist binding into channel gating. In this com-
munication, we explore the role of post-M4 in the function of two prokary-
otic homologs, the pH-activated GLIC and the cystamine-activated ELIC.
using the two voltage electrode clamp apparatus, we show that single alanine
mutations of each of the five C-terminal residues in GLIC has little effect on
the pH50 for activation, with a slight loss of function only occurring upon
mutation of either of the phenylalanine residues F314 and F313 that extend
from post-M4 to interact with the remainder of the transmembrane domain.
Sequential deletions of post-M4 residues, however, have more dramatic
effects. Deletion of the three terminal residues (F316-F314) drops the pH50
from 4.74 down to 4.34. Further deletions lead to a complete loss of activity
showing that the extended length of post-M4 plays a critical role in GLIC
channel activity, as it does with the nAChR. Surprisingly, detrimental effects
of post M4 deletions were not observed with ELIC. In fact, deletion of post-
M4 residues in ELIC typically led to a slight gain in function, with EC50
values for cystamine decreasing from 0.81 mM (wild type) to ~0.50 mM.
Our results highlight distinct functional characteristics of two homologous
pLGICs.
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Background: A central tenet of ligand-receptor theory is that agonists bind
more tightly to active than to inactive receptors. This is a difficult concept to
test experimentally, because in most agonist-receptor systems, the act of as-
sessing agonist binding affinity results in receptor activation. In a1b2g2L
GABAA receptors, the anesthetic etomidate is an allosteric agonist at high
concentrations, and potentiates GABA activation at low concentrations. Sites
mediating both actions were photolabeled with azi-etomidate, identifying the
b2M286 sidechain as a contact point. We used a cysteine substitution and
sulfhydryl modification to study etomidate interactions with this sidechain.
Methods: using two-microelectrode voltage clamp electrophysiology in
Xenopus oocytes, we characterized etomidate agonism and potentiation of
GABA activation in a1b2M286Cg2L GABAA receptors. We studied cova-
lent modification of the b2M286C sidechain by a sulfhydryl-selective
reagent, para-chloromercuribenzenesulfonate (pCMBS) with and without
GABA. Etomidate-dependent protection of the sulfhydryl was also assessed.
Results: Oocyte-expressed a1b2M286Cg2L receptors displayed reduced
sensitivity to GABA, and no agonism by etomidate. However, etomidate
still enhanced GABA-activated currents from a1b2M286Cg2L receptors.
Exposure of a1b2M286Cg2L receptors to pCMBS irreversibly increased
activation by low (EC10) GABA. The apparent rate of pCMBS modifi-
cation increased with addition of GABA. Etomidate in a concentration-
dependent manner reduced the rate of b2M286C modification by pCMBS.
Etomidate protection at b2M286C was enhanced in the presence of
GABA. Conclusions: Etomidate, like azi-etomidate, binds next to the
b2M286 residue. Based on its apparent protectant potency, the affinity of
etomidate for GABA-bound receptors is greater than that for resting recep-
tors, as expected. Our results have important implications for both designing
and interpreting experiments that use mutations to map allosteric modulator/
agonist sites.
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Propofol, a widely used intravenous general anesthetic, potentiates GABA-A
receptor (GABAAR) function at anesthetic concentrations, and ‘‘knock-in’’
mice expressing a single mutation at position 15 in the b3 subunit M2 helix
(bM2-15) have reduced sensitivity to many of the anesthetic effects of
propofol. However, the location of propofol’s binding site(s) remains to be
determined. Here we use a photoactive analog of propofol, [3H]m-azipropo-
fol(2-isopropyl-5-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenol), an aryl diazir-
ine with broad amino acid side chain reactivity, to identify propofol binding
site(s) in affinity-purified, expressed human a1b3 GABAARs in detergent/
asolectin solution. m-Azipropofol acts as a tadpole anesthetic with potency
(EC50 = 3mM) similar to propofol, and it acts as a low efficacy GABAAR
potentiator (Hall et al. 2010, J Med. Chem. 53, 5667). Irradiation of
GABAAR for 30 min at 365nm resulted in [
3H]m-azipropofol photoincorpora-
tion into both the a1 and b3 subunits that was inhibitable by propofol and
non-radioactive m-azipropofol with IC50s of 2853 mM and 6.751 mM,
respectively. Individual amino acids photolabeled by [3H]m-azipropofol
were identified by protein microsequencing of subunit fragments generated
by enzymatic or chemical digestion. In b3, there was propofol-inhibitable
photolabeling of b3Met-286, an amino acid that is photolabeled by [3H]azie-
tomidate in the etomidate binding site at the b3M3-a1M1 interface (Li et al.
2006, J Neurosci. 26, 11599, Chiara et al. 2012, Biochem. 51, 836). In a1,
[3H]m-azipropofol photolabeled a1Ile-239 within a1M1, located one helical
turn below a1Met-236 that is photolabeled by [3H]azietomidate. Consistent
with propofol and m-azipropofol binding to this etomidate site, they com-
pletely inhibit [3H]azietomidate photolabeling with IC50s of 4653 mM and
2353 mM, respectively. Both b3Met-286 and a1Met-236 are in close proxim-
ity to bM2-15, which docking calculations suggest may also be part of this
propofol binding site.
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Background: GABAA receptors are allosterically modulated by a variety of
compounds including etomidate and tetrahydrodeoxycorticosterone (THDOC).
Extrasynaptic abd GABAA receptors mediate tonic inhibition, and may be
more sensitive to modulators than synaptic abg receptors. Studies of concate-
nated subunit assemblies suggests that the subunit arrangement of abd may
vary (1). We compared the modulation by etomidate and THDOC on a1b3d
receptors with different subunit arrangements, and to a1b3g2L receptors.
Methods: Plasmids encoding concatenated GABAA receptor subunit
assemblies and free subunits were obtained from Prof. Erwin Sigel (Bern, Swit-
zerland). Xenopus oocytes were used to express b3-a1-d/b3-a1 and b3-a1-d/
a1-b3 receptors as well as free subunit mixtures. Effects of etomidate
(3 mM) or THDOC (1 mM) on maximal GABA-activated receptor currents
were measured using two-microelectrode voltage-clamp electrophysiology.
Etomidate enhancement of b3-a1-d/b3-a1 was assessed over a broad
[GABA] range, and analyzed with an allosteric model.
Results:High GABA elicited small currents in oocytes expressing b3-a1-d/b3-
a1 and b3-a1-d/a1-b3 receptors. THDOC produced similar large current
enhancements in b3-a1-d/b3-a1 and b3-a1-d/a1-b3 receptors. However,
etomidate produced a greater current enhancement in b3-a1-d/a1-b3 receptors
than in b3-a1-d/b3-a1. Etomidate increased the maximal response of b3-a1-d/
b3-a1 receptors to GABA and produced a small leftward shift in GABA EC50.
Discussion: using concatenated receptor constructs resulted in evidence of
d subunit incorporation that was not seen using free subunit mRNAs. GABA
is a weak partial agonist in a1b3d receptors, while etomidate and THDOC
modulate via different sites. Etomidate efficacy in a1b3d is similar to that in
a1b3g receptors with homologous subunit arrangement, and interactions at
b3/b3 interfaces may be more efficacious than those at b3/a1 interfaces.
Support: NIH (R01GM89745 and P01GM58448)
Reference:
1) Kaur KH et al, J. Biol Chem 2009;284:7889-96
